ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S ...

Across the recent three months, 11 analysts have shared their insights on ACADIA Pharmaceuticals ACAD, expressing a variety ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company with a market capitalization of $3.06 billion, focuses on developing and commercializing innovative medicines to address ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter ...

Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a federal ...

Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares.The firm sees the Delaware court’s verdict in favor of ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET.

Sei Investments Co. lifted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 57.4% during the 4th quarter, according to its most recent 13F filing with the SEC.

Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, ...